Andrew Klein
- Indexed articles, last 90 days
- 2
- Latest publication
- Sep 16, 2026
- Outlet visibility, for Endocrinology Advisor
- Top 5M sites
- Earliest in this view
- Aug 14, 2026
Latest articles
FIERCE Pharma 2026: Cultural Stigma, Misinformation May Contribute to Avoidance of GLP-1 RAs (opens the original)
Read excerpt
While public interest in glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, has driven rapid growth in their prescribing rates, it has introduced an unintended consequence for diabetes care: heightened patient drug avoidance stemming from cultural stigma, brand dilution, and media misinformation. These findings were presented at Fierce Pharma Week 2026, held in Philadelphia, Pennsylvania, at a session on September 15, 2026. “You can take the word ‘Ozempic’ and put a body
Endocrine Society Issues Statement on Testosterone Replacement Therapy for Men With Hypogonadism (opens the original)
Read excerpt
The Endocrine Society recently released a statement on testosterone replacement therapy (TRT) in men with hypogonadism, with recommendations on appropriate testing and prescribing practices. The press release is available on their website.1 The statement highlights key clinical goals to curb misuse, ensure accurate testing, and better define the candidate populations for treatment. Healthcare providers must weigh the benefits of testosterone replacement therapy (TRT) against the risks. Overall,
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Endocrinology Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.